ReviewBone reports2026
Effects of high-dose methotrexate on bone metabolism: A narrative literature review.
Review in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association of Vitamin D Receptor Gene Polymorphisms and Hypovitaminosis D with Reduced Bone Mineral Density in Survivors of Childhood Leukemia: A Study in Algerian Patients.Current issues in molecular biology · 2026Article
- Protective Role of Alpha-Lipoic Acid Against Methotrexate-Induced Osteotoxicity: Mechanisms of Oxidative Stress Regulation and MAPK Pathway Inhibition.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Low-Dose Methotrexate and Bone Health: Pathophysiological and Clinical Perspectives.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) play an important role in oncology, where it is used in high-dose therapy regimens. However, its associated dose-dependent toxicity, including MTX-osteopathy, poses a serious clinical problem, particularly in pediatric oncology. Even in patients with inflammatory rheumatic diseases receiving low doses, rare cases of MTX-osteopathy have been reported. This review provides an updated discussion of the side effects of high-dose MTX (HD-MTX), with the aim of improving understanding of the pathophysiology underlying its effects on bone, identifying potential supportive treatments, and highlighting new areas of research that could enhance the understanding and management of chemotherapy-related adverse effects. Methodology: A review of the available literature was conducted to analyse the impact of HD-MTX on bone tissue. Results: MTX disrupts bone homeostasis and microarchitecture through a variety of cell-specific mechanisms. These effects trigger a cascade of negative outcomes, including abnormalities in macrometric and structural bone histomorphometric parameters, as well as impaired bone healing. Few studies have evaluated the protective effects of adjunctive therapies, and those that do exist demonstrate only partial protection. This highlights the need for further research to develop more effective strategies to prevent MTX-induced bone toxicity. Conclusions: Available data suggest that the effects of HD-MTX involve multiple mechanisms that disrupt bone homeostasis, including impaired osteoblast function, enhanced osteoclastogenesis, altered osteocyte viability, increased bone marrow adipogenesis, and endothelial damage. These changes lead to reduced bone density, compromised microarchitecture, and impaired healing. This highlights the importance of multi-targeted strategies to prevent MTX-induced bone damage and improve skeletal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.